TempraMed Technologies (FRA:9DY) Total Operating Expense: €5.52 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9DY TempraMed Technologies Ltd FRA:9DY
12 GF Score
Price €0.29
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies Total Operating Expense?

TempraMed Technologies FRA:9DY -4.62% 12 Total Operating Expense is €5.52 Mil as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

TempraMed Technologies's Total Operating Expense for the three months ended in Mar. 2026 was €2.31 Mil. TempraMed Technologies's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €5.52 Mil.

TempraMed Technologies Total Operating Expense Related Terms

TempraMed Technologies Total Operating Expense Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Total Operating Expense Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
Total Operating Expense
0.00 3.52 4.60

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only 0.96 0.45 1.56 1.19 2.31
FRA:9DY
12GF Score
TempraMed Technologies Ltd FRA:9DY
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €5.52 Mil mean?
TempraMed Technologies (FRA:9DY) has a Total Operating Expense of €5.52 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on TempraMed Technologies and its competitors.
Is TempraMed Technologies' Total Operating Expense too high?
TempraMed Technologies' current Total Operating Expense is €5.52 Mil. Overall, TempraMed Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' Total Operating Expense compare to ABT and SYK?
TempraMed Technologies' Total Operating Expense of €5.52 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on TempraMed Technologies and its competitors. TempraMed Technologies's current Total Operating Expense is €5.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current Total Operating Expense of €5.52 Mil. The current Total Operating Expense is €5.52 Mil. TempraMed Technologies' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current Total Operating Expense is €5.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
12GF Score

Get the complete analysis for FRA:9DY

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price